News

The Manila Times21h
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...
Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...